Analyst Julian Harrison of BTIG reiterated a Buy rating on Viridian Therapeutics, retaining the price target of $61.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Julian Harrison has given his Buy rating due to a combination of factors that highlight Viridian Therapeutics’ promising future prospects. The submission of the Biologics License Application (BLA) for veligrotug, along with a request for priority review, positions the company for a potential commercial launch by mid-2026. This is supported by the THRIVE-1/2 trials, which demonstrate a less burdensome infusion regimen and significantly reduced infusion time and drug exposure compared to competitors. Additionally, the upcoming Phase 3 REVEAL-1/2 trials for VRDN-003, expected to yield topline data in early to mid-2026, further de-risk the company’s pipeline due to shared binding domains with veligrotug.
Moreover, the strategic royalty financing agreement with DRI is expected to extend Viridian’s cash runway, supporting the commercial launches of both veligrotug and VRDN-003. This agreement provides substantial financial backing, with potential milestone payments and tiered royalties on net sales. The preference among payors for self-administered subcutaneous treatments over intravenous options also strengthens Viridian’s market position, as it aligns with cost-saving measures for healthcare facilities. These factors collectively contribute to a positive outlook for Viridian Therapeutics, justifying the Buy rating.
According to TipRanks, Harrison is a 5-star analyst with an average return of 32.3% and a 54.31% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Cullinan Management, Oruka Therapeutics, and Nektar Therapeutics.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $46.00 price target.